Chemotherapy Plus Targeted Therapies Shows Improved Survival In Advance-stage Lung Cancer Patients

The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.

Read the whole article on Science Daily

More from Science Daily